Showing results (121-130 of 252) with videos related to

Sort By:
Pageof 26
Journal of Medicinal Chemistry|September 9, 2010
Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agentsSteven Fletcher, Erin Pusateri Keaney, Christopher G Cummings, et al.
Organic & Biomolecular Chemistry|January 5, 2006
A dialkynoyl analogue of DOPE improves gene transfer of lower-charged, cationic lipoplexesSteven Fletcher, Ayesha Ahmad, Eric Perouzel, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2007
Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeuticsKatherine J Kayser, Matthew P Glenn, Said M Sebti, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2012
Blocking HIV-1 entry by a gp120 surface binding inhibitorLun K Tsou, Chin-Ho Chen, Ginger E Dutschman, et al.
Oncotarget|June 4, 2015
Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletionHuabo Wang, Lokendra Sharma, Jie Lu, et al.
Chembiochem : a European Journal of Chemical Biology|January 11, 2008
Biophysical properties of CDAN/DOPE-analogue lipoplexes account for enhanced gene deliverySteven Fletcher, Ayesha Ahmad, Wayne S Price, et al.
Biochemical Pharmacology|January 14, 2010
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processesXiaolei Zhang, Peibin Yue, Steven Fletcher, et al.
Investigational New Drugs|April 28, 2026
Prostate cancer cells' growth is decreased by novel MYC inhibitorsBita Nickkholgh, Joseph McGrath, Sivanandane Sittadjody, et al.
Bioorganic & Medicinal Chemistry|November 28, 2012
Novel inhibitors of a Grb2 SH3C domain interaction identified by a virtual screenPhilip C Simister, James Luccarelli, Sam Thompson, et al.
Pageof 26